Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 36Advanced Solid Tumors 20Myelodysplastic Syndromes 14Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 13Advanced Solid Tumor 13Recurrence 10Ovarian Neoplasms 8Neoplasms 8Multiple Myeloma 8Leukemia, Myelomonocytic, Chronic 8Triple Negative Breast Neoplasms 7Solid Tumor 6Myeloproliferative Disorders 6Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Neoplasm Metastasis 5Lymphoma, Large B-Cell, Diffuse 5Lung Neoplasms 5Carcinoma, Hepatocellular 5Advanced Solid Tumour 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Melanoma 4Lymphoma, B-Cell 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Advanced Malignant Solid Tumor 4Advanced Lung Cancer 4Squamous Cell Carcinoma of Head and Neck 3

Interventions

Cyclophosphamide 34Doxorubicin 24fludarabine phosphate 20Vinblastine 20Nivolumab 20Dacarbazine 20Brentuximab Vedotin 20pembrolizumab 19fludarabine 18Mycophenolic Acid 17Whole-Body Irradiation 15Etoposide 15Filgrastim 13Melphalan 12Granulocyte Colony-Stimulating Factor 10Gemcitabine 10Bleomycin 10Tacrolimus 9Radiotherapy 9Prednisone 9Peripheral Blood Stem Cell Transplantation 9Busulfan 9Specimen Handling 8Vincristine 7Sirolimus 7Magnetic Resonance Spectroscopy 7Cyclosporine 7pegfilgrastim 6Stem Cell Transplantation 6Bendamustine Hydrochloride 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × Injections × 1 year × Clear all
NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡